Stockscreener 앱 받기
12.67
0.48%
0.06
시간 외 거래:
12.41
-0.26
-2.05%
전일 마감가:
$12.61
열려 있는:
$12.88
하루 거래량:
4.77M
Relative Volume:
1.62
시가총액:
$1.71B
수익:
$24.30M
순이익/손실:
$-145.57M
주가수익비율:
-9.5263
EPS:
-1.33
순현금흐름:
$-149.17M
1주 성능:
+6.03%
1개월 성능:
+18.86%
6개월 성능:
+87.43%
1년 성능:
+415.04%
1일 변동 폭
$12.25
$13.10
1주일 범위
$12.12
$13.18
52주 변동 폭
$1.03
$13.46
Tango Therapeutics Inc Stock (TNGX) Company Profile
명칭
Tango Therapeutics Inc
전화
(857) 320-4900
주소
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
12.67 | 1.70B | 24.30M | -145.57M | -149.17M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-17 | 개시 | Jefferies | Buy |
| 2024-04-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 개시 | Piper Sandler | Overweight |
| 2023-12-08 | 개시 | B. Riley Securities | Buy |
| 2022-10-20 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 개시 | SVB Leerink | Outperform |
모두보기
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
TNGX: Major clinical milestones for vopimetostat and pipeline updates are expected this year - TradingView
Published on: 2026-02-12 23:58:23 - baoquankhu1.vn
Analysts Set Tango Therapeutics, Inc. (NASDAQ:TNGX) PT at $14.80 - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Guggenheim Keeps Their Buy Rating on Tango Therapeutics (TNGX) - The Globe and Mail
Expert Outlook: Tango Therapeutics Through The Eyes Of 4 Analysts - Benzinga
Guggenheim Issues Positive Forecast for Tango Therapeutics (NASDAQ:TNGX) Stock Price - MarketBeat
Tango Therapeutics CFO sells $126,530 in TNGX stock By Investing.com - Investing.com Canada
Tango Therapeutics CFO sells $126,530 in TNGX stock - Investing.com
Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells 18,452 Shares of Stock - MarketBeat
Weber Barbara, director at Tango Therapeutics, sells $374k in TNGX stock - Investing.com Canada
Commit To Purchase Tango Therapeutics At $10, Earn 25.9% Annualized Using Options - Nasdaq
Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Director Sells 30,519 Shares of Stock - MarketBeat
Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Can Tango Therapeutics (TNGX) climb 37.28% to reach the level Wall Street analysts expect? - MSN
Great Lakes Advisors LLC Invests $3.56 Million in Tango Therapeutics, Inc. $TNGX - MarketBeat
VIX Spike: Will Tango Therapeutics Inc benefit from rising consumer demandMarket Risk Report & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Pancreatic Cancer Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd - Barchart.com
Tango Therapeutics (NASDAQ:TNGX) Sets New 52-Week HighWhat's Next? - MarketBeat
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 53% Price Boost Is Out Of Tune With Revenues - simplywall.st
Analysis Recap: Can Tango Therapeutics Inc be recession proof2025 Sector Review & Stepwise Swing Trade Plans - baoquankhu1.vn
Analysts Set Tango Therapeutics, Inc. (NASDAQ:TNGX) Target Price at $13.00 - Defense World
Tango Therapeutics stock hits 52-week high at 12.65 USD By Investing.com - Investing.com Nigeria
Tango Therapeutics stock hits 52-week high at 12.65 USD - Investing.com India
TNGX Analyst Rating Update: Piper Sandler Raises Price Target | - GuruFocus
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Nasdaq Futures Research-Driven Model - Kalkine Media
TNGX: Leadership shift supports late-stage trials and robust MTAP-deleted cancer pipeline progress - TradingView
Tango Therapeutics (NASDAQ:TNGX) Trading 8.3% HigherShould You Buy? - MarketBeat
TNGX: Smooth leadership transition supports late-stage trials in MTAP-deleted cancers and robust 2026 milestones - TradingView — Track All Markets
Sentiment Review: Will Tango Therapeutics Inc stock recover after earningsEntry Point & Intraday High Probability Alerts - baoquankhu1.vn
Tango Therapeutics (NASDAQ:TNGX) Stock Price Down 8.4%What's Next? - MarketBeat
Tango Therapeutics stock maintains Buy rating at Stifel on encouraging early data - Investing.com Canada
Tango Therapeutics stock maintains Buy rating at Stifel on encouraging early data By Investing.com - Investing.com India
Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 29% - 富途牛牛
Tango Therapeutics (NASDAQ:TNGX) Reaches New 52-Week High – Time to Buy? - Defense World
Does Tango Therapeutics’ (TNGX) CEO Transition Clarify or Complicate Its Precision Oncology Roadmap? - Yahoo Finance
Tango Therapeutics appoints new CEO amid leadership transition - The Globe and Mail
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor - Sahm
Can Tango Therapeutics Inc. stock sustain market leadershipJuly 2025 Macro Moves & Weekly Return Optimization Plans - Улправда
How Tango Therapeutics Inc. stock reacts to oil prices2025 Institutional Moves & Stock Timing and Entry Methods - Улправда
Tango Therapeutics Appoints Dr. Malte Peters as CEO - citybiz
Can Tango Therapeutics Inc. stock resist market sell offsJuly 2025 Macro Moves & Safe Capital Growth Plans - Улправда
Will Tango Therapeutics Inc. stock deliver long term returnsTrade Exit Summary & Daily Price Action Insights - Улправда
Tango Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 8, 2026 - marketscreener.com
Tango Therapeutics' CEO Retires, Successor Appointed; Shares Fall - MarketScreener
Is Tango Therapeutics Inc. stock a defensive play in 2025Dip Buying & Short-Term High Return Ideas - Улправда
Tango Therapeutics announces CEO transition: Barbara Weber to retire, Malte Peters appointed successor - marketscreener.com
Tango Therapeutics appoints Malte Peters as new CEO By Investing.com - Investing.com Australia
Tango Therapeutics appoints Malte Peters as new CEO - Investing.com
Tango Therapeutics Announces Leadership Transition: Barbara Weber, M.D. Becomes Executive Chair as Malte Peters, M.D. Assumes Role of President and CEO - Quiver Quantitative
Tango Therapeutics Inc (TNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tango Therapeutics Inc 주식 (TNGX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Weber Barbara | Director, Executive Chair |
Feb 03 '26 |
Sale |
12.26 |
30,519 |
374,294 |
1,629,254 |
| Crystal Adam | President, R&D |
Feb 03 '26 |
Sale |
12.26 |
18,452 |
226,300 |
187,218 |
| Third Rock Ventures IV, L.P. | 10% Owner |
Oct 23 '25 |
Sale |
10.15 |
477,401 |
4,846,575 |
13,386,574 |
1.24%
0.19%
자본화:
|
볼륨(24시간):